Following administration of a single dose of [U14C]cyanidanol-3 to human volunteers, a mean of 55% of the dose of 14C was excreted in urine; 90% of urine 14C was excreted within 24 h of drug administration. The major urinary metabolites were the glucuronides of (+)-catechin and 3'-O-methyl-(+)-catechin, and the sulphate of the latter. These three conjugates collectively accounted for three quarters of urine 14C. Urinary excretion of unchanged (+)-cyanidanol-3 was 0.1-1.4% dose. (+)-Cyanidanol-3 and metabolites containing the intact flavanol ring system accounted for 90% of urine 14C. Ring scission was, under these conditions, a minor metabolic pathway resulting in the excretion of small amounts of 3-hydroxybenzoic acid, 3-hydroxyhippuric acid and 3-hydroxyphenylpropionic acid. Unchanged (+)-cyanidanol-3 was detected in plasma between 30 min and 12 h after administration. Metabolites (as total 14C) persisted in plasma for at least 120 h after administration.
1. The major biliary metabolites of flavanones in the rat have been identified by chromatographic and spectral methods. 2. Evidence is presented that flavanones and flavanone glycosides, following oral or parenteral administration, undergo glucuronylation and are selectively excreted via the bile. 3. Flavanone glycosides but not unconjugated aglycones may be excreted to a significant extent in bile. 4. The percentage of parenterally administered flavanones excreted in bile varies inversely with the amount administered.
1. The disposition of anagliptin, an orally active, highly selective dipeptidyl peptidase-4 inhibitor, was investigated after a single oral dose of 100 mg/1.92 MBq [(14)C]anagliptin to six healthy men. Almost all the dose (98.2%) was recovered within 168 h: 73.2% in urine and 25.0% in faeces. 2. Anagliptin was rapidly absorbed, with peak plasma concentrations of unchanged drug attained at a mean time of 1.8-h postdose. Mean fraction of the dose absorbed was >73%. Unchanged drug and a carboxylate metabolite (M1) were the major components in plasma, accounting for 66.0 and 23.4% of total plasma radioactivity area under the curve, respectively. 3. Anagliptin was incompletely metabolized, with about 50% dose eliminated as unchanged drug (46.6% in urine and 4.1% in faeces). Metabolism to M1 accounted for 29.2% of the dose. No other metabolite accounted for >1% dose in excreta or yielded measurable systemic exposure. Terminal half-life of anagliptin and M1 was 4.37 and 9.88 h, respectively. Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.
Three young male volunteers excreted 51.5, 33.6 and 55.9% of a single 2 g oral dose of radiolabelled 3-O-methyl-(+)-catechin in urine within 120 h of administration. Excretion of the unchanged compound, however, accounted for only 0.7, 0.1 and 0.2% of the dose. The major urinary metabolites were glucuronides of 3,3'-O-dimethyl-(+)-catechin (15.8% dose) and a glucuronide and a sulphate of 3-O-methyl-(+)-catechin (11.4% and 10.6% dose, respectively). No evidence for demethylation was obtained. 3-O-Methyl-(+)-catechin was detected and measured in plasma by h.p.l.c. 0.5-12 h after administration. Peak levels (11-18 micrograms/ml) were attained within two hours of administration and the half-life of removal from plasma was approx. 140 min. Metabolism of 3-O-methyl-(+)-catechin in man was found to vary significantly from other species, as methylated metabolites (3'-O-methyl ethers) in man represented only about 53% of the urinary metabolites, whereas in the mouse, rat and marmoset, 3'-O-methylation was almost quantitative (Hackett and Griffiths 1981). The glucuronic acid conjugates of 3-O-methyl-(+)-catechin detected in man also differed from those previously reported in the rat. Additionally, sulphate conjugation of 3-O-methyl-(+)-catechin was observed in man although not in other species. 3-O-Methyl-(+)-catechin, unlike (+)-catechin, did not undergo ring fission.
1. Oral administration of 3-palmitoyl-(+)-[U-14C]catechin to rats resulted in the excretion of 63% of the dose in urine, 24% in faeces and 7% as 14CO2 in the 17 days following dosing. Persistent levels of 14C were noted in tissues, and 28 days after dosing 3.7% of the dose was present in the animal body. 2. Biliary excretion accounted for 28.2% of the dose in 48h after dosing. The major biliary metabolite was 3'-O-methyl-(+)-catechin glucuronide. These experiments also demonstrated the dependence of 3-palmitoyl-(+)-catechin on the presence of bile in the intestine for absorption. 3. Studies in vitro showed that intestinal micro-organisms were unable to metabolize 3-palmitoyl-(+)-catechin. The compound did, however, undergo deesterification in plasma and also in liver-perfusion studies. In the latter experiments, conjugates of the liberated (+)-catechin were also formed. 4. Urinary metabolites were predominantly (80%) conjugates of (+)-catechin and 3'-O-methyl-(+)-catechin. Ring scission products and 14CO2 were also excreted but not from rats with ligated bile ducts. These metabolites are therefore considered to arise from biliary metabolites not containing the ester linkage.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.